Apellis Pharma (APLS.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec4

Citigroup Analyst Maintains Buy Rating and Sets Target Price for Apellis Pharmaceuticals

01:07

Dec3

Apellis Pharmaceuticals Inc.'s EMPAVELI® Receives FDA Approval

22:05

Nov28

Geode Capital Management LLC Increases Stake in Apellis Pharmaceuticals

10:13

Nov18

Apellis Pharmaceuticals General Counsel Sold Company Stock

15:06

Nov14

H.C. Wainwright Analyst Maintains Buy Rating on Apellis Pharmaceuticals

23:42

Nov12

Apellis Pharmaceuticals Reports Five-Year Study Results of SYFOVRE® Treatment

12:01

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 458.58 M, Net Income 215.72 M, EPS 1.67

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 178.49 M, Net Income -42.15 M, EPS -0.3344

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 166.8 M, Net Income -92.23 M, EPS -0.7351

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change